Business Context and Reporting Period
Replimune Group, Inc. filed a Form 8-K dated September 9, 2020, reporting the results of its 2020 Annual Meeting of Stockholders. The company’s fiscal year ends March 31. Its common stock trades on Nasdaq under the symbol REPL.
Meeting Results and Key Corporate Actions
- Director elections: Paolo Pucci, Jason Rhodes, Sander Slootweg, and Otello Stampacchia were elected as Class II directors to serve until the 2023 Annual Meeting and until their successors are elected and qualified.
- Auditor ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2021.
Vote Totals
| Proposal | Votes For | Votes Against or Withheld | Other |
|---|---|---|---|
| Paolo Pucci | 28,330,522 | 1,273,120 withheld | 3,193,307 broker non-votes |
| Jason Rhodes | 19,777,234 | 9,826,408 withheld | 3,193,307 broker non-votes |
| Sander Slootweg | 25,184,093 | 4,419,549 withheld | 3,193,307 broker non-votes |
| Otello Stampacchia | 25,182,875 | 4,420,767 withheld | 3,193,307 broker non-votes |
| Auditor ratification | 32,760,379 | 23,161 against | 13,409 abstaining |
Financial Metrics and Liquidity
The filing is limited to annual meeting voting results and does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes, Outlook, and Risks
The filing does not report material changes in financial performance, guidance, outlook, contingencies, unusual items, or new risk factors. The principal reported changes are the election of the Class II directors and ratification of the independent auditor.
Investor Verification Points
- Verify the elected directors’ terms and committee assignments in subsequent filings.
- Confirm PricewaterhouseCoopers LLP’s continued appointment and review any subsequent auditor-related disclosures.
- Use the company’s periodic reports, rather than this 8-K, to assess operating performance, cash runway, debt, liquidity, and clinical or regulatory developments.